Sapablursenの新興薬剤に関する洞察と市場予測：2032年

当レポートでは、主要7ヶ国におけるSapablursen市場について調査し、市場の概要とともに、2027年から2032年までの売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 真性多血症におけるSapablursenの概要

• 製品の詳細
• 臨床開発
  • 臨床試験
  • 臨床試験情報
• その他の開発活動
• 製品プロファイル

第3章 競合情勢環境（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 Sapablursenの市場評価

• 真性多血症に対するSapablursenの市場展望
• 主要7ヶ国市場分析
  • 主要7ヶ国における真性多血症に対するSapablursenの市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

• 参考文献
• レポートの調査手法

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: Sapablursen, Clinical Trial Description, 2022
• Table 2: Sapablursen: General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: Sapablursen Market Size in the 7MM, in USD million (2019-2032)
• Table 6: Sapablursen Market Size in the United States, in USD million (2019-2032)
• Table 7: Sapablursen Market Size in Germany, in USD million (2019-2032)
• Table 8: Sapablursen Market Size in France, in USD million (2019-2032)
• Table 9: Sapablursen Market Size in Italy, in USD million (2019-2032)
• Table 10: Sapablursen Market Size in Spain, in USD million (2019-2032)
• Table 11: Sapablursen Market Size in the United Kingdom, in USD million (2019-2032)
• Table 12: Sapablursen Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: Market Size of Sapablursen in the 7MM, in USD million (2019-2032)
• Figure 2: Market Size of Sapablursen in the United States, in USD million (2019-2032)
• Figure 3: Market Size of Sapablursen in Germany, in USD million (2019-2032)
• Figure 4: Market Size of Sapablursen in France, in USD million (2019-2032)
• Figure 5: Market Size of Sapablursen in Italy, in USD million (2019-2032)
• Figure 6: Market Size of Sapablursen in Spain, in USD million (2019-2032)
• Figure 7: Market Size of Sapablursen in United Kingdom, in USD million (2019-2032)
• Figure 8: Market Size of Sapablursen in Japan, in USD million (2019-2032)

"Sapablursen Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about Sapablursen for Polycythemia Vera in the 7MM. A detailed picture of the Sapablursen for Polycythemia Vera in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the Sapablursen for Polycythemia Vera. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Sapablursen market forecast, analysis for Polycythemia Vera in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Polycythemia Vera.

Drug Summary:

Sapablursen, formerly known as IONIS-TMPRSS6-LRx, is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of transmembrane protease, serine 6, or TMPRSS6, to treat anemia and iron toxicity.

TMPRSS6 is a protein produced in the liver that plays an important role in the regulation of the body's iron homeostasis through the control of the iron regulatory protein hepcidin. Inhibition of TMPRSS6 leads to increased hepcidin production, which results in more effective red blood cell production (erythropoiesis) in the bone marrow and reduced iron toxicity in the liver as a result of improved control of iron availability. Sapablursen is now being invested in a Phase II trial for the treatment of phlebotomy-dependent Polycythemia Vera. 

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the Sapablursen description, mechanism of action, dosage and administration, research and development activities in Polycythemia Vera.
• Elaborated details on Sapablursen regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Sapablursen research and development activity in Polycythemia Vera details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Sapablursen.
• The report contains forecasted sales of Sapablursen for Polycythemia Vera till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Polycythemia Vera.
• The report also features the SWOT analysis with analyst views for Sapablursen in Polycythemia Vera.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Sapablursen Analytical Perspective by DelveInsight

• In-depth Sapablursen Market Assessment

This report provides a detailed market assessment of Sapablursen in Polycythemia Vera in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

• Sapablursen Clinical Assessment

The report provides the clinical trials information of Sapablursen for Polycythemia Vera covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Polycythemia Vera is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Sapablursen dominance.
• Other emerging products for Polycythemia Vera are expected to give tough market competition to Sapablursen and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Sapablursen in Polycythemia Vera.
• Our in-depth analysis of the forecasted sales data of Sapablursen from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Sapablursen in Polycythemia Vera.

Key Questions

• What is the product type, route of administration and mechanism of action of Sapablursen?
• What is the clinical trial status of the study related to Sapablursen in Polycythemia Vera and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Sapablursen development?
• What are the key designations that have been granted to Sapablursen for Polycythemia Vera?
• What is the forecasted market scenario of Sapablursen for Polycythemia Vera?
• What are the forecasted sales of Sapablursen in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Polycythemia Vera and how are they giving competition to Sapablursen for Polycythemia Vera?
• Which are the late-stage emerging therapies under development for the treatment of Polycythemia Vera?

Table of Contents

1. Report Introduction

2. Sapablursen Overview in Polycythemia Vera

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical Studies
  • 2.2.2. Clinical Trials Information
• 2.3. Other Development Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)*

5. Sapablursen Market Assessment

• 5.1. Market Outlook of Sapablursen in Polycythemia Vera
• 5.2. 7MM Market Analysis
  • 5.2.1. Market Size of Sapablursen in the 7MM for Polycythemia Vera
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Sapablursen in the United States for Polycythemia Vera
  • 5.3.2. Market Size of Sapablursen in Germany for Polycythemia Vera
  • 5.3.3. Market Size of Sapablursen in France for Polycythemia Vera
  • 5.3.4. Market Size of Sapablursen in Italy for Polycythemia Vera
  • 5.3.5. Market Size of Sapablursen in Spain for Polycythemia Vera
  • 5.3.6. Market Size of Sapablursen in the United Kingdom for Polycythemia Vera
  • 5.3.7. Market Size of Sapablursen in Japan for Polycythemia Vera

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Option